Skip to main
XNCR

Xencor (XNCR) Stock Forecast & Price Target

Xencor (XNCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 57%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Xencor is a biopharmaceutical company with a promising pipeline of engineered antibodies that target both cancer and autoimmune diseases. With a strong focus on research and development, continued partnership agreements and licensing agreements, and a diverse pipeline of product candidates, Xencor is well-positioned for future success. Furthermore, the company has upcoming clinical data readouts for several of its key programs, which could de-risk potential indications and drive further upside. While clinical and financial risks exist, Xencor has a strong foundation and promising prospects as it continues to advance its innovative therapies.

Bears say

Xencor is a clinical-stage biopharmaceutical company with a single reportable segment focused on discovering and developing engineered antibody therapeutics. Their revenue primarily comes from collaboration and licensing agreements, and they have a diverse pipeline with product candidates targeting cancer and autoimmune diseases. However, with a target dose range not expected to be reached until 2027 and a decision to shift focus and capital away from a low probability Phase 3 study, Xencor's future may be uncertain.

Xencor (XNCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 57% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xencor (XNCR) Forecast

Analysts have given Xencor (XNCR) a Buy based on their latest research and market trends.

According to 7 analysts, Xencor (XNCR) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xencor (XNCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.